Pathology utilisation during COVID-19 outbreaks beyond viral testing: routine coagulation and D-dimer testing

Favaloro, Emmanuel J.; Lay, Michelle; Mohammed, Soma; Vong, Ronny; Pasalic, Leonardo

doi:10.1016/j.pathol.2022.02.013

Cited by 4 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such increases can be compared with another recent report from Australia, which showed general increases in D-dimer testing of up to ninefold in a series of hospital-associated laboratories and according to a timeline of COVID-19 “waves,” with similar increases across all metropolitan hospital sites, where the burden of COVID-19 patients would be highest, as compared with rural/regional sites. 25…”

Section: Tablementioning

confidence: 99%

Editorial Compilation—XIII

Favaloro

Pasalic

Lippi

2023

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 99%

Editorial Compilation—XIII

Favaloro

Pasalic

Lippi

2023

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

“…39 40 Indeed, the entire network of 60 laboratories within NSWHP reported a huge increase in D-dimer requests that could be linked to various waves of SARS-CoV-2 infections and, in some sites, reflecting nearly 10x increases in test requests over similar periods prior to COVID-19. 41…”

Section: Evolution Of Hemostasis Testing—the Contemporary 2020'smentioning

confidence: 99%

“…39,40 Indeed, the entire network of 60 laboratories within NSWHP reported a huge increase in D-dimer requests that could be linked to various waves of SARS-CoV-2 infections and, in some sites, reflecting nearly 10x increases in test requests over similar periods prior to COVID-19. 41 In terms of automation, the entire NSWHP group of (60) laboratories were part of a NSW state-wide tender for instrumentation, which was awarded to Werfen, and the ACL-TOP 50 group of analyzers (350, 550, 750) were rolled out to 60 laboratories (for a total of 75 instruments). Our two Stago StaR Evolutions were replaced with two ACL-TOP 750 instruments and the Stago instruments decommissioned.…”

Section: Evolution Of Hemostasis Testing-the Contemporary 2020'smentioning

confidence: 99%

Evolution of Hemostasis Testing: A Personal Reflection Covering over 40 Years of History*

Favaloro

2023

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

There is no certainty in change, other than change is certain. As Seminars in Thrombosis and Hemostasis celebrates 50 years of publication, I felt it appropriate to reflect on my own 40-year plus scientific career. My career in the thrombosis and hemostasis field did not start until 1987, but the subsequent 35 years reflected a period of significant change in associated disease diagnostics. I started in the Westmead Hospital “coagulation laboratory” when staff were still performing manual clotting tests, using stopwatches, pipettes, test tubes, and a water bath, which we transported to the hospital outpatient department to run our weekly warfarin clinic. Several hemostasis instruments have come and gone, including the Coag-A-Mate X2, the ACL-300R, the MDA-180, the BCS XP, and several StaR Evolution analyzers. Some instruments remain, including the PFA-100, PFA-200, the AggRAM, the CS-5100, an AcuStar, a Hydrasys gel system, and two ACL-TOP 750s. We still have a water bath, but this is primarily used to defrost frozen samples, and manual clotting tests are only used to teach visiting medical students. We have migrated across several methodologies in the 45-year history of the local laboratory. Laurel gel rockets, used for several assays in the 1980s, were replaced with enzyme-linked immunosorbent assay assays and most assays were eventually placed on automated instruments. Radio-isotopic assays, used in the 1980s, were replaced by an alternate safer method or else abandoned. Test numbers have increased markedly over time. The approximately 31,000 hemostasis assays performed at the Westmead-based laboratory in 1983 had become approximately 200,000 in 2022, a sixfold increase. Some 90,000 prothrombin times and activated partial thromboplastic times are now performed at this laboratory per year. Thrombophilia assays were added to the test repertoires over time, as were the tests to measure several anticoagulant drugs, most recently the direct oral anticoagulants. I hope my personal history, reflecting on the changes in hemostasis testing over my career to date in the field, is found to be of interest to the readership, and I hope they forgive any inaccuracies I have introduced in this reflection of the past.

show abstract

“…9 Nonetheless, these changes can be compared with another recent report from Australia, which showed increases in D-dimer testing of up to ninefold according to a timeline of COVID-19 "waves," with similar increases across all metropolitan hospital sites, where the burden of COVID-19 patients would be highest, compared with rural/regional sites. 10 In conclusion, the combination of these two almost independent findings is seemingly suggesting that clinicians have clear in mind that D-dimer is a key biomarker in COVID-19 but also that D-dimeritis (intended as often unscrupulous ordering of D-dimer test) 7 may still be among us.…”

mentioning

confidence: 95%

mentioning

confidence: 99%